Subgroup analyses on patients with ER+/HER2- tumours also showed that DeepGrade was a predictor of recurrence-free survival with an estimated hazard ratio of 2.12 (p = 0.044, 95% CI: 1.02; 4.43) for patients in the DeepGrade-high group compared to those in the DeepGrade-low group, independently of the patient’s age (Fig. 6C-D). The gene discussed is ERBB2; the disease is neoplasm.